Compare Organon & Co. Common Stock (OGN) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Vale SA — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Vale SA trades at $13.19 (market cap $57.30B). The key difference: Vale SA is far larger — about 15.8× Organon & Co. Common Stock's market cap, and Vale SA pays the higher dividend (8.9%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Vale SA for 110 Days on average.
| OGN | VALE | |
|---|---|---|
Market Cap | $3.62B | $57.30B |
Volume | 2,892,999 | 25,010,417 |
Sector | Health | Basic Materials |
52-Week High | $13.81 | $17.82 |
52-Week Low | $5.70 | $11.10 |
Typical Hold Time | 0 Days | 110 Days |
Enterprise Value | $11.04B | $73.54B |
Dividend Yield | 0.58% | 8.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
VALE trades at $13.21, down 2.29% today, with a bearish technical signal and three consecutive quarterly EPS misses. The stock shows mixed fundamentals with a P/E of 26.74 and net income margin of 5.11%, while cash flow improved to $2.42B in 2025. Recent news highlights pressure from US steel expansion plans and rising operational costs.
Analyst consensus is cautious with 57% hold ratings and a $15.93 price target, suggesting 21% upside. Key risks include iron ore price volatility, Brazilian regulatory exposure, and margin compression from cost inflation. The base metals segment growth provides some diversification support amid cyclical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
